Shanghai Pharmaceuticals (HKG:2607, SHA:601607) said its generic version of pentoxifylline passed the National Medical Products Administration's consistency evaluation for generic drugs.
Changzhou Pharmaceutical Factory, a subsidiary, submitted the consistency evaluation application in August 2023, according to a Tuesday disclosure on the Shanghai Stock Exchange.
Pentoxifylline is indicated for treating peripheral artery disease and vascular inner ear disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments